VCM
PSTV

Vanguard Capital Management’s Plus Therapeutics PSTV Stock Holding History

Vanguard Capital Management’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$396K Buy
+97,084
New +$736K ﹤0.01% 3711

Other funds holding PSTV

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Capital Management's PSTV Position: Q1 2026 in Review

Vanguard Capital Management opened a new position in Plus Therapeutics (PSTV) in Q1 2026: 97,084 shares worth $396K. The stake represents ﹤0.01% of the portfolio and ranks #3711 among its holdings.

23 funds tracked by Wall St. Rank hold PSTV as of Q1 2026.

  • Vanguard Capital Management held 97,084 shares of Plus Therapeutics worth $396K as of Q1 2026.
  • Plus Therapeutics was a new Vanguard Capital Management position in Q1 2026.
  • Plus Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q1 2026, its #3711 holding.
  • 23 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2026.

Based on Vanguard Capital Management's 13F filing for Q1 2026, filed 8 May 2026.